Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Eltrekibart · LY-3041658

Monoclonal antibody · developed by ELI LILLY &

Phase 2 Most advanced trial
LLY Developer

What is Eltrekibart?

Eltrekibart is an investigational antibody studied in Ulcerative Colitis, Ulcerative Colitis Chronic.

At a glance

Also known as
LY-3041658
Drug type
Monoclonal antibody
Therapy area
Gastroenterology
Developer
ELI LILLY & (LLY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
WB62WIH13E

Conditions studied

Ulcerative ColitisUlcerative Colitis Chronic

More from ELI LILLY &

Abemaciclib FDA approved Baricitinib FDA approved Donanemab FDA approved Dulaglutide FDA approved Imlunestrant FDA approved Lebrikizumab FDA approved Mirikizumab FDA approved Orforglipron FDA approved Pirtobrutinib FDA approved Selpercatinib FDA approved Tirzepatide FDA approved Brenipatide Phase 3

Follow LLY, the company behind Eltrekibart

See LLY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LLY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.